Program
bicalutamide
Also written as “Bicalutamide”, “ICI176,334-1” and “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”.
Its studies are mostly in Prostatic Neoplasms · Lower Urinary Tract Symptoms · Puberty, Precocious · Gynecomastia, led by 5 companies.
Drug pageBicalutamide: every studyMany companies study it; this page follows only the 21 they lead. All 94 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZenecaits history only | 130 open or running | phase 4since Oct 26, 2005 | Oct 16, 2004 | none ahead |
| Alessa Therapeuticsits history only | 21 open or running | phase 1since Feb 12, 2020 | Feb 12, 2020 | Apr 24, 2027phase 1 · NCT04943536 |
| Kremers Urban Developmentits history only | 20 open or running | phase 1since Dec 23, 2009 | Dec 23, 2009 | none ahead |
| Novartisits history only | 20 open or running | phase 1since Aug 13, 2009 | Aug 13, 2009 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 1since Sep 8, 2009 | Sep 8, 2009 | none ahead |
Also a collaborator on its studies: AbbVie.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 1 study since Oct 16, 2004.
- Oct 26, 2005Phase 4 study in Prostatic NeoplasmsAstraZeneca · NCT00255268 · 15 enrolled · Mexico
- Dec 28, 2007Phase 4 study in Prostatic NeoplasmsAstraZeneca · NCT00590213 · 125 enrolled · Turkey
- Mar 12, 2008Phase 2 study in GynecomastiaAstraZeneca · NCT00637871
- Apr 7, 2008Phase 3 study in Prostatic NeoplasmsAstraZeneca · NCT00657904 · 3,618 enrolled · United States, Canada
- May 2, 20082 phase 3 studies in Prostatic NeoplasmsAstraZeneca · NCT00673205, NCT00672282
- Feb 18, 2009Phase 3 study in Prostatic NeoplasmsAstraZeneca · NCT00846976 · 101 enrolled · United States
- Aug 13, 2009Novartis’s first studies: 2 phase 1 studies in Prostatic NeoplasmsNew to NovartisNovartis · NCT00960310, NCT00959335
- Sep 8, 2009Teva Pharmaceutical Industries’ first studies: 2 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00973050, NCT00972855
- Dec 23, 2009Kremers Urban Development’s first study: phase 1 study in BioequivalencyNew to Kremers Urban DevelopmentKremers Urban Development · NCT01039233 · 60 enrolled · Canada
- Jan 7, 2010Phase 1 study in HealthyKremers Urban Development · NCT01044706 · 60 enrolled · Canada
- Aug 11, 20114 phase 1 studies in HealthyAstraZeneca · NCT01415791, NCT01415778, NCT01416883 and 1 more
- Mar 21, 2019Phase 4 study in Advanced Prostate CancerAstraZeneca · NCT03971110 · 9 enrolled · China
- Feb 12, 2020Alessa Therapeutics’ first study: phase 1 study in Lower Urinary Tract SymptomsNew to Alessa TherapeuticsAlessa Therapeutics · NCT04284761 · 17 enrolled · United States, Australia, New Zealand
- Jun 15, 2021Phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT04943536 · 20 enrolled · United States
Ahead
- Apr 24, 2027Primary completion: phase 1 study in Prostate AdenocarcinomaAlessa Therapeutics · NCT04943536
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT04943536Prostate Adenocarcinoma · United States | 1 | Active, not recruiting | Alessa Therapeutics | Apr 24, 2027 | 20 |
| NCT04284761Lower Urinary Tract Symptoms · United States, Australia, New Zealand | 1 | Completed | Alessa Therapeutics | May 3, 2023 | 17 |
| NCT03971110Advanced Prostate Cancer · China | 4 | Terminated | AstraZeneca | Nov 9, 2022 | 9 |
| NCT01416883Healthy | 1 | Terminated | AstraZeneca | Aug 2010 | 8 |
| NCT01416870Healthy | 1 | Terminated | AstraZeneca | Nov 2010 | 102 |
| NCT01415791Healthy | 1 | Completed | AstraZeneca | Sep 2011 | 8 |
| NCT01415778Healthy | 1 | Completed | AstraZeneca | Nov 2011 | 48 |
| NCT01044706Healthy · Canada | 1 | Completed | Kremers Urban Development | Jul 2005 | 60 |
| NCT01039233Bioequivalency · Canada | 1 | Completed | Kremers Urban Development | Jun 2005 | 60 |
| NCT00973050Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Sep 2003 | 60 |
| NCT00972855Healthy · Canada | 1 | Completed | Teva Pharmaceutical Industries | Sep 2003 | 60 |
| NCT00960310Prostatic Neoplasms | 1 | Completed | Novartis | Jun 2006 | 36 |
| NCT00959335Prostatic Neoplasms | 1 | Completed | Novartis | Aug 2006 | 36 |
| NCT00846976Prostatic Neoplasms · United States | 3 | Completed | AstraZeneca | Jun 2013 | 101 |
| NCT00673205Prostatic Neoplasms · Australia, Austria, Belgium and more | 3 | Completed | AstraZeneca | Aug 2008 | 3,588 |
| NCT00672282Prostatic Neoplasms · Denmark, Finland, Norway and more | 3 | Completed | AstraZeneca | 1,218 | |
| NCT00657904Prostatic Neoplasms · United States, Canada | 3 | Completed | AstraZeneca | Jul 2008 | 3,618 |
| NCT00637871Gynecomastia | 2 | Completed | AstraZeneca | Jun 2005 | |
| NCT00590213Prostatic Neoplasms · Turkey | 4 | Completed | AstraZeneca | 125 | |
| NCT00255268Prostatic Neoplasms · Mexico | 4 | Withdrawn | AstraZeneca | 15 | |
| NCT00094328Puberty, Precocious · United States, Canada, France and more | 2 | Completed | AstraZeneca | May 22, 2008 | 14 |
How it is read
Names in the registry
- “Bicalutamide”, 9 entries
- “ICI176,334-1”, 4 entries
- “bicalutamide”, 2 entries
- “Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)”, 2 entries
- “Casodex 80 mg tablet”, 2 entries
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 10 studies
- Lower Urinary Tract Symptoms, 1 study
- Puberty, Precocious, 1 study
- Gynecomastia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.